The Effect of Zoledronic Acid Infusion in the Bone Loss Observed Following Denosumab Discontinuation in Postmenopausal Women With Low Bone Mass
Phase of Trial: Phase IV
Latest Information Update: 15 Jul 2016
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- 11 Jul 2016 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
- 11 Jul 2016 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.
- 20 Jul 2015 New trial record